Document Detail


Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients.
MedLine Citation:
PMID:  18827961     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IL-23 is the main inductor in Th17 polarization of naive T cells, inducing IL-17 production. IL-17 has been demonstrated to be elevated in ankylosing spondylitis (AS). The p40 subunit is common to IL-12 and IL-23. We assessed serum and synovial levels of p40 IL12/23 in spondyloarthropathy (SpA) patients and the evolution under anti-TNF. SpA patients fulfilling ESSG criteria were included. Healthy volunteers served as controls. P40 IL12/23 was assessed using Human Quantikine ELISA (R&D Systems), and at the same time, BASDAI, ESR, CRP, IL-17, MMP-3. Patients treated with anti-TNF were evaluated again after 10 weeks of treatment. Statistical analysis used Mann Whitney and correlation tests. Twenty-seven SpA outpatients (20 men), mean age 40.3 years, mean disease duration 10.5 years, HLA B27 positive n = 21, peripheral arthritis n = 8, mean BASDAI 45.7, mean CRP 30.7 mg/l, and 24 controls (12 men), mean age 50.4 years, were included. There is no statistical difference in serum levels of p40IL12/23 between patients (mean 77.8 pg/ml) and controls (103 pg/ml) and between patients with axial and peripheral involvement. Levels were higher in HLA B-27 negative patients (p = 0.02). No statistical correlation was found between p40 IL12/40 serum levels and each of BASDAI, ESR, CRP, serum levels of IL 17, MMP 3. Fourteen AS patients were treated with TNF blockers. Whereas significant reduction in BASDAI, ESR, and CRP were obvious after treatment, there was no significant change in serum level of p40 IL12/23. Mean levels of synovial p40 IL12/23 were higher in SpA patients (n = 6; mean 536 pg/ml) compared to osteoarthritis patients (n = 3; 133 pg/ml) and compared with paired serum SpA levels. These results suggest that serum levels of p40 IL-12/23 may not be considered as a biologic tool of disease activity assessment in SpA patients.
Authors:
Daniel Wendling; Jean-Pierre Cedoz; Evelyne Racadot
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-09-27
Journal Detail:
Title:  Clinical rheumatology     Volume:  28     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2008-12-23     Completed Date:  2009-04-08     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  187-90     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, University Teaching Hospital, Boulevard Fleming, 25030 Besançon, France. dwendling@chu-besancon.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Blood Sedimentation
C-Reactive Protein / metabolism
Case-Control Studies
Disease Progression
Female
Humans
Immunoglobulin G / therapeutic use
Interleukin-12 Subunit p40 / blood*,  metabolism*
Interleukin-17 / blood
Male
Matrix Metalloproteinase 3 / blood
Middle Aged
Osteoarthritis / metabolism
Receptors, Tumor Necrosis Factor / therapeutic use
Spondylarthropathies / blood*,  metabolism*
Synovial Fluid / metabolism*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Immunoglobulin G; 0/Interleukin-12 Subunit p40; 0/Interleukin-17; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; 9007-41-4/C-Reactive Protein; EC 3.4.24.17/Matrix Metalloproteinase 3; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy.
Next Document:  Simple sampling strategy for measuring inulin renal clearance.